U.S. Professional Services Stock News

NasdaqGS:PEGA
NasdaqGS:PEGASoftware

A Look At Pegasystems (PEGA) Valuation After Recent Share Price Weakness

Pegasystems stock overview after recent performance shifts Pegasystems (PEGA) has drawn investor attention after a mixed run, with the stock up 0.9% over the past day and 4.7% over the past week, but down over the past month and past 3 months. See our latest analysis for Pegasystems. At a share price of US$35.44, Pegasystems has seen recent short term weakness, with the 30 day share price return down 4.1% and the 90 day share price return down 25.0%. The 3 year total shareholder return of...
NasdaqCM:RR
NasdaqCM:RRMachinery

Is Richtech Robotics (RR) Trading Regulatory Strain for European and Voice-AI Ambitions?

Richtech Robotics recently received a Nasdaq notice for missing the filing deadline for its Form 10-Q for the quarter ended March 31, 2026, even as it announced a prospective partnership with SoundHound AI and a new European distribution agreement with NewConsultancy. These developments highlight a company balancing regulatory compliance pressures with efforts to enhance its robots through voice AI and broaden access across the European Union hospitality and service markets. We’ll now...
NasdaqGS:TBBK
NasdaqGS:TBBKBanks

Did Routine Votes at Bancorp’s (TBBK) Meeting Reveal Pressure on Its Fintech-Credit Balance?

In late May 2026, The Bancorp, Inc. held its annual meeting, where shareholders elected ten directors, endorsed 2025 executive pay on an advisory basis, and ratified Crowe LLP as the independent auditor for 2026. At the same time, regional lenders like The Bancorp faced fresh scrutiny as inflation-driven expectations of further Federal Reserve rate hikes raised questions about the resilience of their credit-dependent business models. With rising rate expectations pressuring regional lenders’...
NasdaqGM:PTGX
NasdaqGM:PTGXBiotechs

Assessing Protagonist Therapeutics (PTGX) Valuation After Positive Rusfertide Data And Icotyde Approval News

Conference spotlight and clinical data as drivers Protagonist Therapeutics (PTGX) is back in focus after highlighting new rusfertide data in polycythemia vera ahead of a major hematology congress, alongside Icotyde’s regulatory approval and early feedback on commercial prospects. See our latest analysis for Protagonist Therapeutics. The share price has reacted strongly to this stream of clinical and conference news, with a 1-day share price return of 7.74% pushing the stock to US$102.79. This...
NYSE:GWW
NYSE:GWWTrade Distributors

A Look At W.W. Grainger (GWW) Valuation As Shares Reach Yearly Highs On Earnings Growth Optimism

W.W. Grainger (GWW) has climbed to yearly-high share levels, with investors seemingly focused on expectations for strong earnings growth rather than any major deals, insider buying, or other one off corporate events. See our latest analysis for W.W. Grainger. At a share price of $1,289.37, Grainger has seen strong short term momentum, with a 30 day share price return of 13.62% building on a 28.45% year to date share price gain. The 5 year total shareholder return of 195.34% highlights how...
NasdaqGM:CRSP
NasdaqGM:CRSPBiotechs

A Look At CRISPR Therapeutics (CRSP) Valuation After Casgevy Launch And Ongoing Gene Editing Pipeline Progress

CRISPR Therapeutics (CRSP) has been back in focus after its stock moved higher on continued progress across its gene editing pipeline, including the commercial rollout of Casgevy and updates on newer programs. See our latest analysis for CRISPR Therapeutics. CRISPR Therapeutics’ recent 9.35% 1 day share price return and 8.72% 30 day share price return, taking the stock to US$56.95, reflects renewed interest following Casgevy’s rollout and fresh updates across its gene editing programs. A...
NYSEAM:NHC
NYSEAM:NHCHealthcare

A Look At National HealthCare (NHC) Valuation After Acquiring Five Skilled Nursing Facilities And Securing New Credit Facilities

National HealthCare (NHC) has just shifted five skilled nursing facilities from management contracts to full ownership of both operations and real estate, backed by a recently secured term loan and revolving credit facility. See our latest analysis for National HealthCare. The new credit facilities and acquisition of the five skilled nursing facilities come after a period of strong momentum, with a 30 day share price return of 12.55% and a year to date share price return of 44.18%, alongside...
NYSE:SMG
NYSE:SMGChemicals

Does Scotts Miracle-Gro’s (SMG) Locked-In Costs And Reaffirmed 2026 Targets Clarify Its Margin Story?

Earlier this week, The Scotts Miracle-Gro Company reaffirmed its full fiscal 2026 guidance, citing roughly 1% year-over-year growth in branded consumer point-of-sale dollars and about 90% of its commodity costs locked in, while also setting August 4, 2026, for its Investor Day focused on mid- to long-term goals. An interesting angle for investors is how this combination of steady consumer demand indicators and pre-secured input costs could underpin the company's confidence in its margin...
NYSE:FLO
NYSE:FLOFood

Assessing Flowers Foods (FLO) Valuation After Prolonged Share Price Weakness

Flowers Foods stock performance snapshot Flowers Foods (FLO) has drawn investor attention after an extended period of weaker returns, with the stock down 15% over the past month and 20% over the past 3 months. See our latest analysis for Flowers Foods. At a share price of $7.30, Flowers Foods has seen its 7 day share price return fall 5.2% and its year to date share price return decline 32.3%, while the 1 year total shareholder return is down 52.6%. This points to fading momentum as investors...
NYSE:RHI
NYSE:RHIProfessional Services

Robert Half (RHI) Is Up 11.3% After Protiviti’s New AI Patent Win And Sector Rally – Has The Bull Case Changed?

In the past week, Robert Half Inc. participated in the 2026 Baird Global Consumer, Technology & Services Conference and saw its shares advance alongside a broad rally in staffing and employment services peers, while its subsidiary Protiviti secured a second U.S. patent for AI-driven automated data set matching technology. This combination of sector-wide optimism and Protiviti’s new AI patent highlights how Robert Half’s consulting and technology capabilities may be increasingly important to...
NYSE:HPE
NYSE:HPETech

Is It Too Late To Consider Hewlett Packard Enterprise (HPE) After Its Rapid Share Price Surge?

If you are wondering whether Hewlett Packard Enterprise (HPE) is still reasonably priced after its recent run, you are not alone. This article focuses squarely on what that current valuation might mean for you. HPE's share price recently closed at US$53.69, with returns of 40.5% over 7 days, 78.7% over 30 days, 122.1% year to date, and 209.9% over the last year, which naturally raises questions about growth potential and how risk is being priced in. Recent headlines around HPE have focused...
NasdaqCM:HYMC
NasdaqCM:HYMCMetals and Mining

Hycroft Mining (HYMC) Unveils 51-Year Mine Plan With $4.3B NPV Estimate Is The Story Changing?

In early June 2026, Hycroft Mining Holding Corporation released an S-K 1300 Technical Report Summary and Initial Assessment for its Nevada Hycroft Mine, outlining a 51-year operation using pressure oxidation milling and heap leach processing with base case assumptions including US$3,600 per ounce gold and US$48 per ounce silver. The study, prepared by independent engineering firms, details life-of-mine payable production of about 10.42 million ounces of gold and 347.46 million ounces of...
NasdaqGS:LEGN
NasdaqGS:LEGNBiotechs

Assessing Legend Biotech (LEGN) Valuation After Positive Early LB2501 CAR T Therapy Results

Legend Biotech (LEGN) is back in focus after early Phase 1 results for LB2501, its in vivo CD19/CD20 CAR-T candidate, showed a 100% response rate and favorable safety at the higher dose in difficult to treat lymphoma. See our latest analysis for Legend Biotech. The LB2501 update comes after a strong run in the stock, with a 7 day share price return of 21.02% and a 90 day share price return of 80.28%. However, the 3 year total shareholder return has declined 50.37%, so recent momentum...
NasdaqGS:ACGL
NasdaqGS:ACGLInsurance

Arch Capital’s Leadership Shift and Debt Moves Could Be A Game Changer For Arch Capital Group (ACGL)

In early June 2026, Arch Capital Group Ltd. priced US$600 million of 5.250% senior notes due 2036 and US$1.40 billions of 5.950% senior notes due 2056, while also launching cash tender offers of up to US$350 million to refinance existing debt and shifting to a single President model under Maamoun Rajeh following David Gansberg’s departure. The decision to expand Rajeh’s remit across insurance, reinsurance, and mortgage alongside large-scale debt issuance highlights Arch Capital’s focus on...
NasdaqGS:OUST
NasdaqGS:OUSTElectronic

Ouster (OUST) Valuation Check As Analyst Support And New LiDAR Deals Reinforce Growth Expectations

Recent analyst coverage of Ouster (OUST) has converged around a single theme: how its lidar and stereoscopic camera platform is gaining traction across real world automation, robotics, and smart infrastructure applications. See our latest analysis for Ouster. The stock’s recent client announcements with FieldAI and ARGUS, together with the launch of Rev8 and the Stereolabs acquisition, sit against strong momentum, with a 30 day share price return of 64.65% and a 1 year total shareholder...
NYSE:KTB
NYSE:KTBLuxury

Can Kontoor Brands (KTB) Turn Limited Beer-Ink Jeans Hype Into Lasting Brand Relevance?

In late May 2026, Molson Coors Beverage Company announced its third collaboration with Kontoor Brands’ Wrangler label, releasing a limited-edition Coors Banquet x Wrangler festival collection that includes jackets, tees, hats and 250 “Beer Chords” jeans printed with chords from Chase Rice’s new single using beer-based ink. This unconventional use of beer-based ink and music integration underscores how Kontoor is experimenting with culturally resonant, scarcity-driven collaborations to keep...
NasdaqGM:NAMS
NasdaqGM:NAMSBiotechs

Assessing NewAmsterdam Pharma (NAMS) Valuation As New Obicetrapib Data Heads To Major Scientific Conference

Why new obicetrapib data matters for NewAmsterdam Pharma (NAMS) NewAmsterdam Pharma (NasdaqGM:NAMS) is back in focus after announcing upcoming presentations of new safety and efficacy data for its oral hypercholesterolemia therapy, obicetrapib, at a major scientific conference. For investors, these data updates offer another reference point on how the company’s late stage pipeline is progressing within cardiometabolic disease, an area where many patients still face limited or hard to tolerate...
NYSE:RVTY
NYSE:RVTYLife Sciences

A Look At Revvity (RVTY) Valuation After Recent Share Price Momentum And Margin Expansion Narrative

What recent returns signal about Revvity stock Without a specific headline event setting the tone, Revvity (RVTY) has drawn investor attention through its recent performance, with the stock showing positive returns over the past week, month, and past 3 months. Over the past week, Revvity is up about 1.2%, adding to an advance of roughly 10.9% over the past month and 12.1% over the past 3 months. For context, the stock’s 1 year total return sits near 13.5%, while the 3 year and 5 year total...
NYSE:MET
NYSE:METInsurance

Assessing MetLife (MET) Valuation As Recent Share Performance Draws Investor Attention

MetLife stock performance snapshot MetLife (MET) has drawn investor attention after recent price moves, with the stock last closing at $83.46. The company reports annual revenue of $77.58b and net income of $3.43b, supported by multiple global business segments. See our latest analysis for MetLife. Recent trading has been firm, with a 1 day share price return of 3.09% and a 90 day share price return of 16.19%. The 5 year total shareholder return of 52.11% points to momentum that has built...
NYSE:VRT
NYSE:VRTElectrical

Vertiv Targets AI Data Center Water Risks With PurgeRite NearZero Launch

Vertiv Holdings Co (NYSE:VRT) has launched PurgeRite NearZero, a fluid management service for data centers focused on sharply reducing water use. The service targets AI and high density deployments, aiming to improve system cleanliness and support environmental and regulatory priorities. PurgeRite NearZero expands Vertiv's specialized critical infrastructure services portfolio with an ESG oriented offering for data center operators. Vertiv's launch of PurgeRite NearZero comes at a time when...
NYSE:NNN
NYSE:NNNRetail REITs

How Upgraded Cash Flow Guidance And Acquisitions At NNN REIT (NNN) Have Changed Its Investment Story

In late May 2026, NNN REIT raised its AFFO and core FFO per share guidance after reporting strong operating performance, high 98.6% occupancy, and closing US$145,000,000 of acquisitions across 41 properties with long-term net leases. This combination of upgraded guidance, robust leasing metrics, and ongoing portfolio growth highlights how NNN REIT is leaning on its net-lease retail model to reinforce cash flow resilience. We’ll now examine how the upgraded AFFO and core FFO guidance...
NYSE:SWK
NYSE:SWKMachinery

Portfolio Streamlining And Trade Partnerships Might Change The Case For Investing In Stanley Black & Decker (SWK)

Stanley Black & Decker has continued to reshape its portfolio by selling non-core assets while maintaining its 50-year record of dividend increases, and its DEWALT brand has expanded trade support through new SkillsUSA and WorldSkills partnerships, as well as ongoing executive outreach via conferences now past or upcoming. This combination of business streamlining, sustained dividend growth, and deeper engagement with professional tradespeople highlights management’s focus on a leaner,...
NYSE:GD
NYSE:GDAerospace & Defense

Is It Time To Reconsider General Dynamics (GD) After Its Recent Share Price Pullback?

Wondering if General Dynamics at around US$341.50 is offering fair value right now, or if the price is running ahead of what the business is worth. The stock has eased slightly in the short term, down 2.1% over the past week and 2.2% over the past month, while still sitting on a 26.7% return over 1 year and 98.5% over 5 years. Recent headlines have focused on General Dynamics' ongoing role in the Aerospace & Defense sector and how defense spending trends could influence demand for its...
NasdaqGM:DAVE
NasdaqGM:DAVEConsumer Finance

Is It Too Late To Consider Dave (DAVE) After Strong Multi Year Share Price Gains?

Wondering if Dave at US$261.69 still offers value or if most of the opportunity is already priced in? This article walks through what the current valuation signals are really saying. The stock has been choppy in the short term, with the share price down 2.7% over the last week and 0.8% over the last month, but still up 19.2% year to date and 25.1% over the past year. That kind of mixed performance often follows periods of very large multi year gains, where early investors reassess risk and...